Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Rating) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 209,800 shares, an increase of 10.8% from the November 15th total of 189,300 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 109,200 shares, the short-interest ratio is currently 1.9 days.

Insider Activity at Pasithea Therapeutics

In other news, major shareholder Eric Shahinian purchased 57,647 shares of the company's stock in a transaction that occurred on Wednesday, September 28th. The stock was bought at an average cost of $1.19 per share, with a total value of $68,599.93. Following the completion of the purchase, the insider now owns 1,781,705 shares in the company, valued at $2,120,228.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pasithea Therapeutics

A hedge fund recently raised its stake in Pasithea Therapeutics stock. Vanguard Group Inc. grew its stake in Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Rating) by 104.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 159,844 shares of the company's stock after purchasing an additional 81,705 shares during the period. Vanguard Group Inc. owned approximately 0.60% of Pasithea Therapeutics worth $201,000 at the end of the most recent reporting period. Institutional investors own 20.64% of the company's stock.

Pasithea Therapeutics Price Performance

About Pasithea Therapeutics

(Get Rating)

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.

Featured Articles

• Get a free copy of the StockNews.com research report on Pasithea Therapeutics (KTTA)
• Which Two Bluechip Tech Companies Have Raised Their Guidance?
• Should You Worry About Elon Musk Selling His Tesla Shares?
• Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
• This is no Time to Buy Lennar but the Time is Coming
• Game-Changing News For Mullen Automotive

Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.